IRCT20220215054023N1 IRCT 2022-04-27 Sheikh Zayed Medical College/Hospital, Rahim Yar Khan Effectiveness of Thalidomide in Transfusion Dependent Thalassemia patients Effectiveness of Thalidomide in Transfusion Dependent Thalassemia patients 2022-06-01 anticipated 55 Complete https://irct.ir/trial/61970 interventional Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Health service research. N/A Beta thalassemia is genetic disorder which is caused by insertions and deletions in chromosome number 11. The disease is treated by blood transfusions which leads to iron over load and demand for chelation therapy. Some patients do not respond to this treatment and suffer from complications. Although treatment with hydroxyurea has leads to improved conditions by reducing transfusion demand, but some patients do not respond to this treatment. Hence, other treatment modalities which induce fetal hemoglobin are being explored. The aim of this study is to see the effectiveness of thalidomide in treating beta thalassemia patients. Intervention 1: Intervention group: Patients diagnosed with beta thalassemia diagnosed according to clinical characteristics and hemoglobin electrophoresis were included in this study according to the selection criteria. At the time of treatment the patients will interviewed and tested for pre-treatment variables which include hemoglobin levels, transfusion rate. All the patients will then be given 2-5mg/kg thalidomide for 6 months as prescribed by the consultant and these variables will be tested again. Response rate will be tested on the basis of operational definition. The principal investigator will follow up with all the patients and see post-treatment results. Drug used in the study is Capsule Thalido(Thalidomide) with strength 50mg and 100mg will ne given as 2-5mg/kg in once daily dose for 6 months manufactured by ATCO laboratories. Intervention 2: Control group: This group will not receive any type of treatment as assigned to interventional group. Effectiveness will be measured in interventional group only. Yes - There is a plan to make this available What will be shared: Effectiveness of Thalidomide in Transfusion Dependent Thalassemia Patients This study will be conducted at Department of Pediatrics, Sheikh Zayed Medical College/Hospital, Rahim Yar Khan. This study will be conducted after approval from Ethical Review Board (ERB) of Sheikh Zayed Hospital and University of Health Sciences, Lahore. Performa, attached with the synopsis, will be filled by the principle investigator. Patients diagnosed with beta thalassemia diagnosed according to clinical characteristics and hemoglobin electrophoresis were included in this study according to the selection criteria. At the time of treatment the patients will interviewed and tested for pre-treatment variables which include hemoglobin levels and transfusion rate. All the patients will then be given 2-5mg/kg thalidomide for 6 months as prescribed by the consultant hematologist and these variables will be tested again. Response rate will be tested on the basis of operational definition. The principal investigator will follow up with all the patients and see post-treatment results. When: Starting 6 months after publication To whom: For people working in academic institutions Conditions: This data will de used for research purposes and also improve the treatment of beta thalassemia Where to obtain: Contact the relevant person via phone number, email addresses or postal How to obtain: Just contact the relevant person via phone number, email addresses or postal to request to access data Comments: